Immuno-Oncology In Vitro Assays
By Ben Tyrrell and Katie Chapple, Sartorius Stedim Biooutsource
We offer a wide range of assay types and formats to characterize immune-oncology monoclonal antibodies (mAbs). In this application note, we discuss our recently developed assay format to characterize checkpoint inhibitor mAbs, specifically discussing those that target the PD-1 PD-L1 pathway.
Targeting immune checkpoints such as the PD-1 PD-L1 pathway has proven in recent years to be an effective treatment approach resulting in a range of approved mAbs that bind PD-1 or its ligand PD-L1. The checkpoint inhibitor pathways continue to be an area of intensive research and development to bring other Mab treatments to the market. Characterizing the mechanism of action (MoA) of these molecules requires complex assays using primary cells because the MoA rely upon the interaction between T cells and antigen presenting cells.